Aplisol market outlook improves on rising TB screening demand

The Business Research Company says the Aplisol market is set to grow through 2026 as tuberculosis screening, public health programs and healthcare spending increase. North America led the market in 2025, while Asia-Pacific is expected to grow fastest.

Why it matters: - Aplisol is tied to tuberculosis detection, so demand rises when TB screening expands across hospitals, clinics and public health programs. - The market outlook matters because tuberculosis remains a global health issue and a major driver of diagnostic testing. - Growing healthcare budgets and preventive care efforts can increase use of TB skin tests in more countries.

What happened: - The Business Research Company released an outlook saying the Aplisol market is improving as global demand increases. - The report says the market through 2026 is shaped by tuberculosis burden, screening programs, occupational testing and access to affordable diagnostics. - The report also says renewed TB surveillance, migration-related screening, public health funding and early detection programs should support market growth. - Aplisol is a purified protein derivative used in the tuberculin skin test to identify tuberculosis infections. - The test is given by intradermal injection and measures the immune response to components of Mycobacterium tuberculosis. - A positive result suggests possible TB exposure, but further testing is needed to confirm active disease.

The details: - The report lists continued reliance on tuberculosis skin tests, expanded public health screening campaigns, hospital and clinic-based TB monitoring, latent TB detection and occupational health testing as key trends. - Tuberculosis growth is being driven by drug-resistant strains, HIV co-infections, socioeconomic disparities, higher global mobility, underreporting and delays in treatment linked to stigma. - The UK Health Security Agency said TB cases in the United Kingdom rose from 4,380 in 2022 to 4,850 in 2023, a 10.7% increase. - The report says that rise supports demand for Aplisol. - Healthcare spending is also boosting the market because diagnosis and follow-up add to total health costs. - The UK Office for National Statistics reported a 5.6% nominal increase in total healthcare spending from 2022 to 2023, compared with 0.9% growth in 2022. - The same report said long-term health and social care expenditure rose 2.8% in real terms in 2022. - The market report covers Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - In 2025, North America held the largest share of the Aplisol market. - Asia-Pacific is expected to grow the fastest during the forecast period. - The 2026 report package includes market attractiveness scoring, TAM analysis, a company scoring matrix, Excel forecasting dashboards, market hotspots infographics and updated graphics and tables. - The company offers a free sample report and a full report online: More information and the full report.

Between the lines: - The report frames Aplisol demand as a proxy for broader TB surveillance intensity, not just drug or product demand. - North America’s current lead suggests mature screening infrastructure, while Asia-Pacific’s faster growth points to rising testing needs in higher-growth markets. - The inclusion of TAM tools and forecasting dashboards signals that the report is aimed at market planning, not only clinical readers.

What's next: - More TB screening and prevention programs could keep Aplisol demand rising through the forecast period. - Public health funding and occupational testing requirements may remain key demand drivers. - The report points to continued regional divergence, with North America leading near term and Asia-Pacific gaining speed.